JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer

This study is designed to compare the safety and efficacy of JSKN003 versus T-DM1 in unrespectable locally advanced and/or metastatic HER2-positive breast cancer participants previously treated with trastuzumab and taxane.

Trial Details

NCT ID
NCT06846437
Phase
PHASE3
Sponsor
Shanghai JMT-Bio Inc.
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • JSKN003
  • Trastuzumab emtansine (T-DM1)
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • 1\. Voluntarily agree to participate in the study and sign the informed consent.
  • Age≥18 years old.
  • Patients with unresectable locally advanced or metastatic breast cancer confirmed by histology or cytology.
  • Confirmed to be HER2 positive (HER2-positive is defined as IHC 3+ or IHC 2+ with ISH positive) by the pathology department of participating study c…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →